Cellular glutathione as a determinant of the sensitivity of colorectal tumour cell-lines to ZD2767 antibody-directed enzyme prodrug therapy (ADEPT)

British Journal of Cancer

Volumn 83, Issue 2, 2000, Pages 267-269

  Monks, N R ^a   Calvete, J A ^a   Curtin, N J ^c   Blakey, D C ^b   East, S J ^b   Newell, D R ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

^c NONE

Author keywords

ADEPT; Alkylating agent; Buthionine sulfoximine; Glutathione; ZD2767

Indexed keywords

ANTIBODY; BUTHIONINE SULFOXIMINE; CARBOXYPEPTIDASE G2; CHLORAMBUCIL; CHLORMETHINE; GLUTATHIONE; MELPHALAN; PRODRUG; ZD 2767;

ANIMAL CELL; ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; ARTICLE; CANCER CELL CULTURE; COLORECTAL CANCER; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG POTENTIATION; DRUG SENSITIVITY; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL;

EID: 0034131048     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2000.1240     Document Type: Article

References (11)

1. Alaoui-Jamali MA, Panasci L, Centurioni GM, Scheeter R, Lehnert S and Batist G (1992) Nitrogen mustard-DNA interaction in melphalan-resistant mammary carcinoma cells with elevated intracellular glutathione and glutathione-S-transferase activity. Cancer Chemother Pharmacol 30: 341-347
2. Blakey DC, Burke PJ, Davies DH, Dowell RI, East SJ, Eckersley KP, Fitton JE, McDaid J, Melton RG, Niculescu-Duvaz IA, Pinder PE, Sharma SK, Wright AF and Springer CJ (1996) ZD2767, an improved system for antibody-directed enzyme prodrug therapy that results in tumour regressions in colorectal tumour xenografts. Cancer Res 56: 3287-3292
3. Chen T (1977) In situ detection of mycoplasma contamination in cell cultures by fluorescent Hoechst 33258 stain. Exp Cell Res 104: 255-262
4. Cotgreave IA and Moldeus P (1986) Methodologies for the application of monobromobimane to the simultaneous analysis of soluble and protein thiol components of biological systems. J Biochem Biophys Methods 13: 231-249
5. Friedman HS, Dolan ME, Kaufmann SH, Colvin OM, Griffith OW, Moschel RC, Schold SC, Bigner DD and Ali-Osman F (1994) Elevated DNA polymerase α, DNA polymerase β, and DNA topoisommerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross resistant to nitrosoureas and topotecan. Cancer Res 54: 3487-3493
6. Hall AG and Tilby MJ (1992) Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies. Blood Rev 6: 163-173
7. Hayes JD and Wolf CR (1990) Molecular mechanisms of drug resistance. Biochem J 272: 281-295
8. Hogarth LA, Rabello CMA and Hall AG (1999) Measurement of reduced glulathione using high-pressure liquid chromatography. Methods in Molecular Medicine 28:91-94
9. Skehan P, Storeng R. Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S and Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107-1112
10. Smith CV, Jones DP, GuenthnerTM, Lash LH and Lauterburg BH (1996) Compartmentation of glutathione: implications for the study of toxicity and disease. Toxicol Appl Pharmacol 140: 1-12
11. Springer CJ, Dowell R, Burke PJ, Hadley E, Davies DH, Blakey DC, Melton RG and Niculescu-Duvaz I (1995) Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT). J Med Chem 38: 5051-5065